Drug
Uprifosbuvir clinical trials
Also written MK-3682.
- studies test it
- 6
- open now
- 0
- in phase 3
- 0
- first study started
- 2013
How studies write it
Studies that test it under each name
Name
Development codes
Studies by the year they started
6 studies that test it; most in 2016 (3)
| Year | Studies |
|---|---|
| 2013 | 1 |
| 2015 | 2 |
| 2016 | 3 |
By phase
A phase 1/2 study counts in both.
- Phase 1
- 2
- Phase 2
- 5
What it is tested for
Each study’s main condition, where its own words name it.
Who runs them
Industry 6 · Other 0
Often tested with
Tested in the same studies.
Ruzasvir (5) · Grazoprevir (2) · Elbasvir (2) · Ribavirin (1) · MK-3682B (1) · Itraconazole (1)
Studies
Open first, then newest update. How each study uses uprifosbuvir is read from its arms, and is right about nine times in ten.
Testing it · 6
- Efficacy and Safety of Uprifosbuvir (MK-3682) + Ruzasvir (MK-8408) in Treating Hepatitis C Virus Infection Genotypes 1-6 (MK-3682-041)TerminatedPhase 2Merck Sharp & Dohme LLCNCT02956629Written as Uprifosbuvir
- Efficacy and Safety of Grazoprevir (MK-5172) and Uprifosbuvir (MK-3682) With Elbasvir (MK-8742) or Ruzasvir (MK-8408) for Chronic Hepatitis C Virus (HCV) Genotype (GT) 3, GT4, GT5, and GT6 Infection (MK-3682-012)CompletedPhase 2Merck Sharp & Dohme LLCNCT02332720Written as Uprifosbuvir
- Efficacy and Safety of Grazoprevir (MK-5172) and Uprifosbuvir (MK-3682) With Elbasvir (MK-8742) or Ruzasvir (MK-8408) for Chronic Hepatitis C Genotype (GT)1 and GT2 Infection (MK-3682-011)CompletedPhase 2Merck Sharp & Dohme LLCNCT02332707Written as Uprifosbuvir
- Efficacy and Safety of Uprifosbuvir (MK-3682) With Ruzasvir (MK-8408) in Adults With Chronic Hepatitis C Genotype 1, 2, 3, 4, 5 or 6 Infection (MK-3682-035)TerminatedPhase 2Merck Sharp & Dohme LLCNCT02759315Written as Uprifosbuvir 450 mg
- A Study of the Pharmacokinetics of Uprifosbuvir (MK-3682) and Ruzasvir (MK-8408) in Participants With Moderate and Severe Hepatic Insufficiency (MK-3682-029)CompletedPhase 1Merck Sharp & Dohme LLCNCT02666352Written as Uprifosbuvir
- Single and Multiple Dose Study of Uprifosbuvir (MK-3682/IDX21437) in Healthy and Hepatitis C Virus (HCV)-Infected Participants (MK-3682-001)CompletedPhase 1/2Merck Sharp & Dohme LLCNCT01974687Written as Uprifosbuvir
Codes
What other systems call uprifosbuvir · ClinicalTrials.gg INT000957
- MeSH (NLM) C000627758uprifosbuvirConfirmed ClinicalTrials.gov, NLM
- UNII (FDA) JW31KPS26SUPRIFOSBUVIRConfirmed FDA, NLM, Wikidata
- Wikidata Q27281714uprifosbuvirConfirmed FDA, NLM, Wikidata
- NCI Thesaurus C152805UprifosbuvirOne source FDA
- DrugBank DB15206One source Wikidata
| System | Code | Name there | Checked by |
|---|---|---|---|
| MeSH (NLM) | C000627758 | uprifosbuvir | Confirmed ClinicalTrials.gov, NLM |
| UNII (FDA) | JW31KPS26S | UPRIFOSBUVIR | Confirmed FDA, NLM, Wikidata |
| Wikidata | Q27281714 | uprifosbuvir | Confirmed FDA, NLM, Wikidata |
| NCI Thesaurus | C152805 | Uprifosbuvir | One source FDA |
| DrugBank | DB15206 | — | One source Wikidata |
“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.